替格瑞洛对ACS患者冠脉介入术后血清cTnⅠ、NT-proBNP及CKMB水平的影响  

Effect of Ticagrelor on serum cTnⅠ,NT⁃proBNP and CKMB levels after coronary intervention in patients with ACS

作　　者：齐素霞 苏冉 刘莹 王莹 朱凌凌 QI Suxia;SU Ran;LIU Ying;WANG Ying;ZHU Lingling(Department of Cardiology,Xingtai Central Hospital,Xingtai,Hebei,China,054000)

机构地区：[1]邢台市中心医院心内科,河北邢台054000

出　　处：《分子诊断与治疗杂志》2024年第11期2055-2058,共4页Journal of Molecular Diagnostics and Therapy

基　　金：河北省医学科学研究重点课题(20180241);邢台市科技计划项目(2022ZC121)。

摘　　要：目的 分析替格瑞洛对急性冠脉综合征(ACS)患者介入术后血清肌钙蛋白(cTnⅠ),N端B型脑钠肽前体(NT-proBNP)及肌酸激酶同功酶(CK-MB)水平的影响。方法 选取2022年6月至2023年11月邢台市中心医院收治的行经皮冠状动脉介入治疗的ACS患者126例,采用随机数字表法将126例个患者分为对照组62例(予以常规治疗)与观察组64例(予以替格瑞洛治疗)。对比两组血脂水平[甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)]、cTnⅠ、NT-proBNP、CK-MB水平、血小板聚集功能[血小板最大聚集率(MPAR)、P2Y12反应单位(PRU)]、心血管不良事件以及不良反应发生情况。结果 治疗6个月后,两组TG、TC、LDL-C、cTnⅠ、NT-proBNP、CK-MB水平均降低,且观察组水平比对照组低,差异有统计学意义(P<0.05);治疗6个月后,两组MPAR、PRU均降低,且观察组水平低于对照组,差异有统计学意义(P<0.05);观察组(4.68%)在随访期间出现的不良心脏事件的总发生率低于对照组(16.13%),差异有统计学意义(P<0.05);两组在用药期间均出现严重不良反应,两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论 替格瑞洛可有效降低ACS患者介入手术后的血脂水平,提高其血小板聚集功能,减少不良心脏事件的发生风险,具有一定的安全性。Objective To investigate the impact of Ticagrelor on serum markers(cTnⅠ,NT⁃proBNP,CK⁃MB)in ACS patients following coronary intervention.Methods A total of 126 ACS patients who underwent percutaneous coronary intervention were selected from June 2022 to November 2023.They were divided into two groups:62 cases in the control group(treated with conventional therapy)and 64 cases in the observation group(treated with Ticagrelor)based on the different therapeutic regimens.The comparison included lipid levels (triglyceride(TG)),total cholesterol(TC),low density lipoproteins cholesterol(LDL⁃C),cTnI,NT⁃proBNP,CK⁃MB levels,platelet aggregation function(Maximum platelet aggregation rate(MPAR)),P2Y12 reaction unit(PRU),adverse cardiovascular events,and the occurrence of adverse reactions.Results After 6 months of treatment,the levels of TG,TC,LDL⁃C,cTnI,NT⁃proBNP,and CK⁃MB were reduced in both groups.The levels in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).Additionally,after 6 months of treatment,MPAR and PRU were reduced in both groups.The levels in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).The overall incidence of adverse cardiac events during follow⁃up was lower in the observation group(4.68%)than in the control group(16.13%),the difference was statistically significant(P<0.05).Adverse reactions occurred in both groups during the treatment period,but there was no statistical significance in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Ticagrelor effectively reduces lipid levels,improves platelet aggregation function,and reduces the risk of adverse cardiac events in ACS patients after interventional procedures.It also has a favorable safety profile.

关 键 词：替格瑞洛 ACS cTnⅠ NT-PROBNP CK-MB 

分 类 号：R541.4[医药卫生—心血管疾病]